ADXN
Price
$9.01
Change
+$0.44 (+5.13%)
Updated
Jun 11 closing price
Capitalization
9.4M
PHAT
Price
$9.04
Change
+$0.07 (+0.78%)
Updated
Jun 11 closing price
Capitalization
631.12M
56 days until earnings call
Interact to see
Advertisement

ADXN vs PHAT

Header iconADXN vs PHAT Comparison
Open Charts ADXN vs PHATBanner chart's image
Addex Therapeutics
Price$9.01
Change+$0.44 (+5.13%)
Volume$1.34K
Capitalization9.4M
Phathom Pharmaceuticals
Price$9.04
Change+$0.07 (+0.78%)
Volume$4.5M
Capitalization631.12M
ADXN vs PHAT Comparison Chart
Loading...
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADXN vs. PHAT commentary
Jun 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADXN is a StrongBuy and PHAT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 12, 2025
Stock price -- (ADXN: $9.01 vs. PHAT: $9.04)
Brand notoriety: ADXN and PHAT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADXN: 22% vs. PHAT: 142%
Market capitalization -- ADXN: $9.4M vs. PHAT: $631.12M
ADXN [@Biotechnology] is valued at $9.4M. PHAT’s [@Biotechnology] market capitalization is $631.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $353.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.4B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADXN’s FA Score shows that 2 FA rating(s) are green whilePHAT’s FA Score has 0 green FA rating(s).

  • ADXN’s FA Score: 2 green, 3 red.
  • PHAT’s FA Score: 0 green, 5 red.
According to our system of comparison, ADXN is a better buy in the long-term than PHAT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PHAT’s TA Score shows that 6 TA indicator(s) are bullish.

  • PHAT’s TA Score: 6 bullish, 4 bearish.

Price Growth

ADXN (@Biotechnology) experienced а +10.41% price change this week, while PHAT (@Biotechnology) price change was +92.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.88%. For the same industry, the average monthly price growth was +14.10%, and the average quarterly price growth was +6.14%.

Reported Earning Dates

ADXN is expected to report earnings on May 15, 2025.

PHAT is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHAT($631M) has a higher market cap than ADXN($9.4M). ADXN YTD gains are higher at: 28.643 vs. PHAT (11.330). ADXN has higher annual earnings (EBITDA): -12.19M vs. PHAT (-272.12M). PHAT has more cash in the bank: 212M vs. ADXN (3.35M). ADXN has less debt than PHAT: ADXN (43.8K) vs PHAT (204M). PHAT has higher revenues than ADXN: PHAT (81.9M) vs ADXN (556K).
ADXNPHATADXN / PHAT
Capitalization9.4M631M1%
EBITDA-12.19M-272.12M4%
Gain YTD28.64311.330253%
P/E RatioN/AN/A-
Revenue556K81.9M1%
Total Cash3.35M212M2%
Total Debt43.8K204M0%
TECHNICAL ANALYSIS
Technical Analysis
PHAT
RSI
ODDS (%)
Bearish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
87%
MACD
ODDS (%)
Bullish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 1 day ago
84%
Declines
ODDS (%)
Bearish Trend 23 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RDWBX12.040.06
+0.50%
American Funds Dvlpg Wld Gr&Inc R2
PPUPX15.45N/A
N/A
Principal LargeCap Growth I R5
GGEAX22.98N/A
N/A
Nationwide Global Sust Eq A
GCEBX9.49N/A
N/A
Goldman Sachs Clean Energy Income A
CGJAX67.58-0.22
-0.32%
Calvert US Large Cap Growth Rspnb Idx A

ADXN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADXN has been loosely correlated with ANVS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ADXN jumps, then ANVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADXN
1D Price
Change %
ADXN100%
+5.08%
ANVS - ADXN
43%
Loosely correlated
-2.78%
CVM - ADXN
39%
Loosely correlated
+2.48%
PHAT - ADXN
28%
Poorly correlated
+0.78%
SGMO - ADXN
26%
Poorly correlated
+0.72%
MOLN - ADXN
24%
Poorly correlated
-2.35%
More

PHAT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHAT has been loosely correlated with TNFA. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAT jumps, then TNFA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAT
1D Price
Change %
PHAT100%
+0.78%
TNFA - PHAT
39%
Loosely correlated
-6.70%
ATRA - PHAT
36%
Loosely correlated
-2.30%
PRME - PHAT
35%
Loosely correlated
-1.29%
RGNX - PHAT
35%
Loosely correlated
+3.98%
ABOS - PHAT
34%
Loosely correlated
-3.39%
More